Want to see NPCE full AI Analyst Report?
NPCE Stock Chart & Stats
$14.81
$0.13(0.89%)
At close: 4:00 PM EDT
$14.81
$0.13(0.89%)
Day’s Range― - ―
52-Week Range$8.61 - $19.60
Previous CloseN/A
Volume268.93K
Average Volume (3M)181.28K
Market Cap
$481.23M
Enterprise Value$560.15
Total Cash (Recent Filing)$51.70M
Total Debt (Recent Filing)$69.93M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 10, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding34,324,272
10 Day Avg. Volume169,331
30 Day Avg. Volume181,278
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)26.55
Price to Sales (P/S)5.05
P/FCF Ratio-44.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.33Price Target Upside37.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.56
Revenue Forecast (FY)$100.30M
Bulls Say, Bears Say
Bulls Say
RNS Adoption And Revenue GrowthSustained double-digit RNS growth, alongside all-time highs in active prescribers, accounts and patient pipeline, indicates increasing clinical adoption and expanding utilization across comprehensive epilepsy centers.
High Gross Margin And Operating LeverageGross margins above 80% and operating expenses growing slower than revenue support a scalable device model. Improving cost discipline and upgraded margin guidance could help NeuroPace convert commercial growth into progressively lower losses.
Proprietary Data And AI DifferentiationA large proprietary intracranial EEG dataset can strengthen algorithm development, therapy personalization and physician engagement. ECoG Assistant extends the RNS platform beyond hardware, potentially deepening competitive differentiation and adoption over time.
Bears Say
Persistent Losses And Negative Cash GenerationAlthough losses and cash burn are improving, NeuroPace has not reached self-funding operations. Continued negative cash generation could require additional financing and may constrain investment in commercialization, research and regulatory programs.
High Leverage And Limited Equity CushionThe capital structure leaves limited balance-sheet flexibility relative to debt obligations. If operating losses persist or cash needs rise, elevated leverage could increase refinancing risk and reduce the company’s ability to absorb execution setbacks.
FDA Delay To IGE Label ExpansionThe regulatory setback delays potential access to a broader idiopathic generalized epilepsy market and creates timing uncertainty. Additional analyses, submissions and review steps may consume resources before the indication can contribute to growth.
NeuroPace News
NPCE FAQ
What was Neuropace, Inc.’s price range in the past 12 months?
Neuropace, Inc. lowest stock price was $8.61 and its highest was $19.60 in the past 12 months.
What is Neuropace, Inc.’s market cap?
Neuropace, Inc.’s market cap is $481.23M.
When is Neuropace, Inc.’s upcoming earnings report date?
Neuropace, Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 79 days.
How were Neuropace, Inc.’s earnings last quarter?
Neuropace, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.218 by $0.038.
Is Neuropace, Inc. overvalued?
According to Wall Street analysts Neuropace, Inc.’s price is currently Undervalued.
Does Neuropace, Inc. pay dividends?
Neuropace, Inc. does not currently pay dividends.
What is Neuropace, Inc.’s EPS estimate?
Neuropace, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Neuropace, Inc. have?
Neuropace, Inc. has 34,324,272 shares outstanding.
What happened to Neuropace, Inc.’s price movement after its last earnings report?
Neuropace, Inc. reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.218. Following the earnings report the stock price went down -3.256%.
Which hedge fund is a major shareholder of Neuropace, Inc.?
Currently, no hedge funds are holding shares in NPCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeuroPace Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.33 (37.29% Upside)
$20.33 (37.29% Upside)
Blogger Sentiment
Neutral
NPCE Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 320.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.60%
Trailing 12-Months
Company Description
Neuropace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
NPCE Company Deck
NPCE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid commercial momentum and improving non‑GAAP profitability metrics, highlighted by double‑digit RNS growth (21%+) and upgraded full‑year guidance and margin outlook. Strategic progress was underscored by the AI product launch (ECoG Assistant), deep proprietary EEG data (27M+ recordings), and ongoing model training and remote care development. The principal negative item was the FDA's determination that the IGE PMA supplement was not approvable in its current form, which introduces regulatory timing uncertainty and the need for additional analyses—however, the agency remained interactive and recommended the SIR process, and management expects to pursue an amendment. Other smaller headwinds included a significant decline in service revenue and modest gross margin pressure. On balance, operational momentum, product innovation, and improved adjusted profitability substantially outweigh the setbacks, though regulatory risk remains a key watch item.View all NPCE earnings summariesNPCE Stock 12 Month Forecast
Average Price Target
$20.33
▲(37.29% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Tactile Systems Technology
―
RxSight
―
Ceribell, Inc.
―
Ownership Overview
16.64% Insiders
9.69% Mutual Funds
41.46% Other Institutional Investors
16.05% Public Companies and
Individual Investors